UVC disinfection technology shown to inactivate Candida auris and Candida albicans

MEMPHIS, Tenn., June 16, 2021 / PRNewswire / – The Tru-D® UVC disinfection device has been shown to be effective against Candida auris and Candida albicans in both direct and indirect line of sight, according to a new study, “Inactivation of Candida auris and Candida albicans by Ultraviolet-C,” in Infection Control and Hospital Epidemiology (I ME). The study was conducted at the University of North Carolina Hospital, an acute tertiary care hospital in Chapel Hill, North Carolina.

The Tru-D is the only portable UVC system on the market with patented Sensor360® technology, which calculates the exact dose of UVC energy needed to inactivate viruses and pathogens in a room while taking space variables such as size, shape, surface reflection and Content to be compensated. The device emits a measured dose of UVC energy from a single point in the room, thus eliminating any pathogens remaining in the room. In this study, the Tru-D The device was set for the vegetative bacterial cycles, which varied from 17 to 19 minutes.

“This study shows that Tru-D Ability of the device to disable both C. auris and C. albicans with significant log10 Reductions both in direct line of sight and in indirect (shaded) areas “, Alice Brewer, MPH, CIC, CPHQ, FAPIC, Director of Clinical Affairs for Tru-D SmartUVC said. “Because of the unique ability of the Tru-D Device for measuring the amount of UVC released, the robot was able to record this high log10 Cuts. Devices with set cycle times may not release enough energy into the room to achieve these results. ”

Candida auris is a emerging fungal pathogen that is often resistant to antifungal drugs. It is a serious global health threat and has caused serious infections with high mortality rates in many countries. Candida auris of environmental health services can survive for at least seven days. Candida albicans is a type of yeast – a unicellular fungus – that is a normal part of the microbes that live in the gastrointestinal tract. However, various factors can favor the microbial balance C. albicanswhich can get the fungus out of control and cause a yeast infection called candidiasis.

“This study is further proof of the effectiveness of our device and also provides additional support Tru-D SmartUVC’s Mission to Deliver the Cleanest Healthcare Environments for Patients and Staff ” Chuck Dunn, President of Tru-D SmartUVC said. “Although manual cleaning is still a critical part of disinfection, this study reflects the findings of many other studies that a layered approach that includes improved disinfection protocols is important for a comprehensive infection prevention program.”

The Tru-D Robots are one way hospitals and healthcare facilities improve care for all patients. Add Tru-Ds Improved UVC disinfection technology for existing hospital cleaning protocols has been shown to provide a cleaner hospital environment for patients. Visit Tru-D.com for more information.

About Tru-D®
Tru-D® SmartUVC, now a PDI solution, expands the PDI portfolio from surface disinfection to entire room disinfection. Only the Tru-D Robot delivers an automated, measured dose of UVC light to consistently inactivate pathogens on hard, non-porous surfaces in a room during a cycle. Operate the Tru-D Pesticide device ensures a significant reduction in pathogens on hard, non-porous surfaces in direct and shady areas. Validated by more than 20 independent studies that Tru-D The automated metered dispensing functions and real-time usage tracking capabilities of the device make it one of the most advanced UVC systems on the market.

About PDI
At PDI, we never forget who we all work for. That’s why we offer a wide range of evidence-based, market-leading solutions for interventional care, nursing environment, and patient care, all of which help reduce preventable infections, control healthcare costs, and ultimately help save lives. All of this is part of our daily passion for Be The Difference®. For more information, visit www.pdihc.com.

Media contact:
Christin Yates
[email protected]


Comments are closed.